The functional studies of amyloid fibrils and their toxicity

By

Abigail Kegomoditswe Elias B.AppSc. (Hons.)

A thesis submitted for the Degree of Doctor of Philosophy

in the

School of Chemistry and Physics

The University of Adelaide



January 2015

Table of Contents

	AB	STRA	ACT	x
	DE	CLAI	RATION	xii
	AC	KNO	WLEDGEMENTS	xiii
	Ab	brevia	ntions	xiv
1.	IN	ΓROD	DUCTION	1
	1.1	Bac	kground	1
	1.2	Prot	tein folding	3
	1.3	Am	yloid fibril formation	4
	1.4	Stru	octure of amyloid fibrils	6
	1.5	Dise	eases associated with amyloid fibrils	7
	1.6	Prot	tein quality system	12
	1.7	Pur	pose of the study	14
	1.8	Lin	kage between Publications	15
2 ar			e semen enhancer of HIV infection along with fragments from its central region, f s that are toxic to neuronal cells	
	2.1	Abs	stract	16
	2.2	Intr	oduction	18
	2.3	Exp	perimental Procedures	21
	2.3	.1	Predictions of amyloidogenic regions	21
	2.3	.2	Peptide synthesis	21
	2.3	.3	Amyloid fibril formation and Thioflavin T (ThT) fluorescence assay	21
	2.3	.4	Transmission electron microscopy	22
	2.3	.5	Circular Dichroism (CD) spectroscopy	22
	2.3	.6	Cell toxicity assays	22
	2.3	.7	Cell viability	23
	2.4	Res	ults	24
	2.4	.1	SEVI is predicted to have two distinct amyloidogenic regions	24
	2.4	.2	SEVI peptide fragments PAP248-271 and PAP257-267 form amyloid fibrils	28
	2.4	.3	SEVI and its fibrillar fragments PAP248-271 and PAP257-267 are toxic to PC 13	2 cells
	2.5	DIS	CUSSION	40
	2.6	AC	KNOWLEDGEMENTS	43
3	SE	VI and	d its fragment help HIV-1 attach to host cells via coreceptors CCR5 and CXCR4	44

3.1	Ab	stract	44
3.2	Int	roduction	46
3	3.2.1	The HIV epidemic	46
3	3.2.2	Human Immunodeficiency Virus (HIV)	47
3	3.2.3	HIV structure	48
3	3.2.4	Sexual transmission of HIV	49
3	3.2.5	Replication strategy for HIV-1	50
3.3	Ma	terials and Methods	53
3	3.3.1	Virus Stocks	53
3	3.3.2	Cell culture	53
3	3.3.3	Affinofile cell assays	53
3	3.3.4	Effect of SEVI on viral infectivity	54
3	3.3.5	Cytotoxicity assays	54
3	3.3.6	MTT assay	54
3.4	Re	sults	55
3	3.4.1	SEVI and its fragments are not toxic to JC 53 cells	55
3.5	Dis	scussion	59
3.6	Ac	knowledgement	61
		racellular molecular chaperone, Clusterin inhibits fibril formation and suppresses	
		associated with the SEVI peptide	
4.1		stract	
4.2		roduction	
		Intracellular quality control mechanisms	
	1.2.2	Extracellular quality control mechanisms	
	1.2.3	Function of clusterin	
4.3		perimental Methods	
	1.3.1	Fibril formation	
	1.3.2	Thioflavin T binding assay	
	1.3.3	Transmission electron microscopy	
	1.3.4	Cellular Toxicity	
	1.3.5	MTT assay	
4.4		sults	
	1.4.1	Fibril formation of SEVI with varying concentration of clusterin	
4	1.4.2	The effect of clusterin to preformed SEVI fibrils	88

	4.4.3	Clusterin inhibits the toxicity of SEVI to PC 12 cells	90
	4.5	Discussion	92
	4.5.	The effect of clusterin on the aggregation and fibril formation of SEVI	92
	4.5.2	Clusterin inhibits the toxicity of SEVI to cells	94
	4.6	Acknowledgements	95
5	Amy	vloid fibrils formed by bovine milk α_s 2-casein are toxic to PC-12 cells	96
	5.1	ABSTRACT	96
	5.2	INTRODUCTION	98
	5.2.	Casein Amyloid formation	99
	5.2.2	2 Casein micelle structure and functions	101
	5.2.3	Caseins as molecular chaperones	103
	5.2.4	Amyloid fibrils and EGCG	104
	5.3	MATERIALS AND METHODS	106
	5.3.	Purification of α_{s1} and α_{s2} casein from α_{s} -casein	106
	5.3.2	Thioflavin T binding	106
	5.3.3	3 Transmission Electron Microscopy	106
	5.3.4	Cellular toxicity of α_{s2} -casein	107
	5.3.5	5 MTT assay	108
	5.4	RESULTS	109
	5.4.2	Effects of EGCG on α_{s2} -CN amyloid fibrils formation	114
	5.5	DISCUSSION	119
	5.5.	Inhibition of fibril formation by α _{s2} -CN by EGCG	120
	5.6	ACKNOWLEDGEMENTS	121
6	Con	clusions	122
	6.1	Future directions	124
	6.1.	Cytotoxicity of SEVI to PC 12 cells	124
	6.1.2	The effect of clusterin in vivo	124
	6.1.3	The effect of SEVI fragments on viral infection	125
	6.1.4	Mechanism of toxicity of α_{s2} -CN	125
	6.1.5	The effect of on αs2-CN viral infection	126
	6.1.6	The effect of on αs2-CN tissue mammary glands	126
_	D.f.		120



List of Tables

Table 1-1: Human neurodegenerative diseases associated with the deposition in brain tissue	
of amyloid fibril aggregates (Chiti and Dobson, 2006, Taylor et al., 2002)	.9
Table 1-2: Human non- neuropathic diseases associated with amyloid fibril deposits (Chiti	
and Dobson, 2006)1	0
Table 4-1: Alternative names given to clusterin (Jenne and Tschopp, 1992)	76

List of Figures

Figure 1.1: Schematic diagram of protein folding and misfolding
Figure 1.2: The difference between amorphous and amyloid fibrillar aggregation4
Figure 1.3: Schematic representation of the possible mechanism of formation of amyloid
fibrils by a globular protein5
Figure 1.4: Scheme of cross- β structure of a mature amyloid fibril with a densely packed two-
layer β -sheet structure
Figure 1.5: Molecular model of an amyloid fibril derived from cryo-EM analysis of SH3
domain fibrils (center)
Figure 2.1: Amyloidogenic propensity of SEVI27
Figure 2.2: Characterization of SEVI and its fragments after incubation at 37 °C with shaking
at 700 rpm
Figure 2.3: Far-UV CD spectra of 0.25 mg/mL of the peptides
Figure 2.4: Concentration-dependent cytotoxicity of native (prefibrillar) and fibrillar SEVI.35
Figure 2.5: Concentration-dependent cytotoxicity of native and fibrillar SEVI, PAP248-271
and PAP257-267 to CACO-2 cells
Figure 2.6: Concentration-dependent cytotoxicity of native and fibrillar α_{s2} -casein (0.5 mM)
to CACO-2 cells
Figure 3.1: Phylogenetic tree of HIV and SIV. Figure from Kuiken (1999)48
Figure 3.2: The HIV genome and virion. Adapted from (Kuiken, 1999)49
Figure 3.3: Schematic overview of the HIV-1 replication cycle. Figure from Engelman and
Cherepanov (2012)
Figure 3.4: Concentration-dependent cytotoxicity of SEVI (●) and PAP248-271 (■) to JC 53
cells

Figure 3.5: SEVI average enhancement (n=3) of HIV-1 infection of JC 53 cells by R5- (ADA
(•), YU-2 (▼), JRCSF (•)), X4 (HXB2 (■)), and dual (89.6 (▲)) viruses57
Figure 3.6: Average enhancement (n=3) of HIV-1 infection of JC 53 cells by R5- (ADA (●),
YU-2 (♥), JRCSF (♦)), X4 (HXB2 (■)), and dual (89.6 (▲)) viruses in the presence of
varying concentrations of amyloidogenic PAP248-271.
Figure 4-1: A schematic representation of the protein folding and off-folding pathway65
Figure 4-2: The protein quality control network involves the actions of many molecular
chaperones to assist the folding of proteins into their native conformations to prevent
misfolding of proteins.
Figure 4-3: The ubiquitin–proteasome pathway.
Figure 4-4: A schematic representation of mechanism for the chaperone action of clusterin to
prevent the amorphous aggregation of target proteins
Figure 4-5: Effect of clusterin on fibril formation of 2 mg/mL SEVI at varying concentrations
of clusterin incubated at 37° C for two days at pH 7.0
Figure 4-6: TEM of the effect of different concentrations of clusterin on SEVI fibril
formation87
Figure 4-7: The effect of clusterin on pre-formed SEVI.
Figure 4-8: The TEM micrographs of clusterin on pre-formed SEVI incubated at 37° C for
two days at pH 7.290
Figure 4-9: Effects of clusterin on cytotoxicity of SEVI (2mg/mL)91
Figure 5.1: Molecular model showing structure of casein micelle99
Figure 5.2: Schematic representation of the formation of a casein micelle
Figure 5.3: The structure of EGCG
Figure 5.4: Concentration-dependent toxicity of α_{s2} -CN in both the native and fibrillar forms.
109

Figure 5.5: Time-dependent toxicity of pre-incubated α_{s2} -CN	11
Figure 5.6: Electron micrographs of α _{s2} -CN (5μM) after A 24 h, B 48 h, C 96 and D 144 h	
incubation at 50°C, showing fibril formation. Scale bar, 1 µm1	13
Figure 5.7: The time-dependent fluorescence analysis of fibril formation by α_{s2} -CN in the	
presence and absence of EGCG	15
Figure 5.8: Electron micrographs of α_{s2} -CN with varying concentration of EGCG. α_{s2} -CN (2)	50
$\mu M)$ with (A) 0.05 $\mu M,$ and (B) 2 μM EGCG after 144 h incubation	16
Figure 5.9: Effect of EGCG on αs2-CN induced PC-12 cell toxicity1	17

ABSTRACT

Amyloid fibrils are a form of highly ordered, β-sheet protein structure found in many sites in the body. Fibril formation occurs when intermediates along the protein-folding pathway irreversibly enter the off-folding pathway to form highly ordered amyloid fibrils. Amyloid fibril formation is of considerable research interest because of its intimate association with a wide range of debilitating diseases, including Alzheimer's, Huntington's and Parkinson's diseases and type II diabetes. Recently, it has been found that amyloid fibrils enhance human immunodeficiency virus (HIV-1) infection. Semen contains a fibril forming component that significantly increases the ability of HIV-1 to infect cells. This component is associated with peptide fragments of prostatic acid phosphatase and has been termed semen-derived enhancer of viral infection (SEVI). SEVI acts at the virus entry stage and only boots infectivity when the peptide has folded into highly structured arrays of amyloid fibrils. The work presented in this thesis describes the broader roles of SEVI in HIV-1 infection including its toxicity to neuronal and epithelial cells as well as the toxicity of α_{s2} -casein (milk fibril forming protein). Firstly, the amyloidogenic regions of SEVI are identified by the use of computer algorithms. Accordingly, these regions were synthesised to examine their individual fibril-forming propensity. Fragments from the central regions formed fibrils of similar morphology to SEVI at physiological pH and temperature. Fibril formation was assessed via thioflavin T assay, circular dichroism spectrometry and transmission electron microscopy (TEM). In this study the toxicity of SEVI and its amyloidogenic fragments to neuronal and epithelial cells was investigated. SEVI and its fragments were toxic to neuronal cells but not to confluent epithelial cells.

Secondly, the coreceptors used by SEVI and its amyloidogenic fragments are identified. HIV enters the cell by the interaction of glycoprotein (gp) 120 envelope with the cellular

differentiation (CD) 4 protein and secondary coreceptors. Affinofile assays showed that SEVI and its fragments use CCR5 and CXCR4 secondary coreceptors to enhance HIV-1 entry to the host cells. Additionally the ability of clusterin to inhibit fibril formation by SEVI was investigated. Clusterin inhibited fibril formation by SEVI in a concentration dependent manner thereby inhibiting the cytotoxicity associated with the fibrils.

Lastly, work detailing the toxicity of fibrils formed by milk protein α_{s2} -casein is presented. α_{s2} -Casein forms fibrils spontaneously under physiological conditions. These fibrils have been found in *corpora amylacea*, an amyloid condition that infrequently develops within the mammary tissue of cows. The use of cell toxicity assays show that fibrils formed by α_{s2} -casein were toxic to pheochromocytoma (PC) 12 cells. Furthermore, the use of Thioflavin T assay and TEM showed that a polyphenol epigallocatechin-3-gallate (EGCG), a component found in green tea extracts, inhibits fibril formation by α_{s2} -casein. Previous research has found that, EGCG can reduce fibril formation and cellular toxicity of various fibril-forming proteins. EGCG has also been shown to inhibit SEVI enhancement of HIV infection in a manner dependent on the ability of EGCG to disrupt SEVI fibril formation, providing proof of principle for the potential of anti-fibril agents as inhibitors of HIV infection.

DECLARATION

I certify that this work contains no material that has been accepted for the award of any other

degree or diploma in any university or other tertiary institution and, to the best of my

knowledge and belief, contains no material previously published or written by another

person, except where due reference has been made in the text. In addition, I certify that no

part of this work will, in the future, be used in a submission for any other degree or diploma

in any university or other tertiary institution without prior approval of the University of

Adelaide and where applicable, any partner institution responsible for the joint-award of this

degree.

I consent to this copy of my thesis when deposited in the University Library, being made

available for loan and photocopying, subject to the provision of the Copyright Act 1968. The

author acknowledges that copyright of published works contained within this thesis resides

with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web,

via the University's digital research repository, the Library catalogue and also through web

search engines, unless permission has been granted by the University to restrict access for a

period of time.

Abigail Kegomoditswe Elias

31st January 2015

- xii -

ACKNOWLEDGEMENTS

I would like to express my sincere gratitude to my supervisor Professor John Carver, you have been amazing. I will forever be grateful for your dedication, support and supervision over the past four years. Being in the Carver laboratory was a blessing because of you. You have a good heart and pray that God blesses everything you do.

I would also like to thank my co supervisor, Ian Musgrave, a man who is always happy, thank you for your help. It has been a great pleasure and honour working under your direction and supervision over the past four years.

Special thanks to Drs Yanqin Liu, Daniella Williams and Antonio Calabrese and the rest of Carver Laboratory team, Katy, Nick and Ranzhao for your technical assistance and the positive influence. Your support and friendship has been invaluable.

To my family, my man and kids, thank you for your support, believe and allowing me the opportunity to fulfil my dream. You have been a source of strength and I will forever love you. I look forward to spending more quality time with you.

To my late Papa and Mama, I am proud and forever thankful for what you have done for me. Thank you for your sacrifices so that I can have better education. I believe I have made you proud. I will always love you and may souls rest in peace. Thanks also to by two sisters Mosarwana and Kerapetse and my brother Outlwile for unconditional love and encouragement.

Finally, thanks be to God who gives victory through our Lord Jesus Christ. This work has been possible because of your grace, mercies and blessings.

Abbreviations

 α_{s2} -CN alpha_{S2}-casein

κ-CN kappa-casein

AIDS acquired immunodeficiency syndrome

CACO-2 epithelial colon carcinoma cells

CA corpora amylacea

CA caspid

CCR5 C chemokine receptor 5 (R5)

CXCR4 CXC chemokine receptor 4 (X4)

CD4 cluster of differentiation

CD circular dichroism

CLI complement-lysis inhibitor

CMA chaperone-mediated autophagy

CMV cytomegalovirus

CSF cerebrospinal fluid

DNA deoxy ribonucleic acid

DMEM Dulbecco's modified eagle medium

DMSO dimethyl sulfoxide

EGCG (-)-epigallocatechin-3-gallate

Env envelope

ER endoplasmic reticulum

ERAD endoplasmic reticulum-associated protein degradation

FPLC fast protein liquid chromatography

gp glycoprotein

HIV human immune virus

HPLC high performance liquid chromatography

HSPs heat-shock proteins

LAMP2A lysosome-associated membrane protein type-2A

MA matrix

MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide

NC nucleocaspid

PAP prostatic acid phosphatase

PC12 pheochromocytoma-12

PCD protein conformational disorders

PCP Pneumocystis carinii pneumonia

PR protease

QTOF2 quadruple time of flight

RCM_K-CN reduced and carboxymethylated kappa-casein

RNA ribonucleic acid

RT reverse transcriptase

SAP serum amyloid P component

SD standard deviation

SEVI semen-derived enhancer of viral infection

TEM transmission electron microscopy

ThT thioflavin T

UV ultraviolet